Table of contents
- Trial overview
- Who can participate
- What is being measured
- Trial phase and design
- Vaccines being compared
- Key patient terms
Trial overview
The available clinical trial is titled Characterization of antibodies in the nose after influenza vaccination and is authorised.[1] It is an interventional study, which means researchers actively give vaccines and then measure the body’s response.[1]
The study is linked to influenza vaccination research and includes A/DARWIN/9/2021 (H3N2) – LIKE STRAIN (A/NORWAY/16606/2021, MEDI 355293) in the trial data provided.[1] The brief summary says the study aims to compare quantitative and qualitative differences in antibody responses between intranasal and intramuscular vaccination.[1]
Who can participate
The trial is designed for healthy individuals.[1] The source does not give more detailed inclusion or exclusion rules, so the exact age range, health limits, or other requirements are not available here.[1]
Because the study focuses on healthy people, it is meant to show how the immune system responds in a group without known illness in the source data.[1]
What is being measured
The main endpoint is the fold change in influenza-specific IgA in nasal fluid at day 21 after vaccination.[1] A fold change means how much the level rises or falls compared with the starting point.[1]
IgA is a type of antibody found in mucus and other body surfaces, and in this study it is measured in the nose to understand local immune response.[1] The trial compares this response after intranasal vaccination with the response after intramuscular vaccination.[1]
Trial phase and design
This is a Phase 3 study.[1] Phase 3 studies usually look at how a treatment performs in a larger or more defined group after earlier testing has already been done, although the source only states the phase and not the full development history.[1]
The study is interventional and includes 60 participants.[1] The purpose is to compare immune responses after different ways of giving influenza vaccination, not to describe long-term follow-up or disease treatment outcomes.[1]
Vaccines being compared
The trial compares two influenza vaccine approaches: a nasal spray vaccine and an injection into the muscle.[1] In the source, the nasal product is Fluenz Tetra nasal spray suspension and the injected product is Vaxigrip Tetra suspension for injection.[1]
This comparison helps researchers see whether the route of vaccination changes the antibody response in the nose.[1] The study is focused on measuring immune response differences rather than on treating an active illness.[1]
Key patient terms
Interventional study: a study where researchers give a treatment or vaccine and then watch what happens.[1]
Endpoint: the main result the study is designed to measure.[1]
Influenza-specific IgA: a type of antibody linked to flu protection, measured here in nasal fluid.[1]
Intranasal: given through the nose.[1]
Intramuscular: given as an injection into a muscle.[1]
Day 21: the time point 21 days after vaccination when the main measurement is taken.[1]
